Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

Eluxadoline & Diarrhea-predominant IBS (IBS-D)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Eluxadoline has now been granted marketing authorization for IBS-D on both sides of the Atlantic, but it is still considered as a second-line agent by the NICE.
Dothel et al. 2018 Exp Opin Invest Drugs 27: 251-263…

References (Sources)

Advancements in drug development for diarrhea-predominant irritable bowel syndrome (IBS)
Dothel et al. 2018 Exp Opin Invest Drugs 27: 251-263
Review
Spotlight on eluxadoline for the treatment of patients with irritable bowel syndrome with diarrhea
Fragkos 2017 Clinical and Experimental Gastroenterology 10: 229-240

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!

Eluxadoline & Diarrhea-predominant IBS (IBS-D)

Welcome to meRfi Microbiome!

Navigation

Contents

References (Sources)

AI Chat